Format

Send to

Choose Destination
Int Immunol. 2016 Jul;28(7):339-48. doi: 10.1093/intimm/dxw020. Epub 2016 Apr 7.

Immune checkpoint inhibition in ovarian cancer.

Author information

1
Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan jnkhmns@kuhp.kyoto-u.ac.jp.
2
Department of Obstetrics and Gynecology, Kinki University, Higashiosaka, Osaka, 577-8502, Japan.
3
Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

Abstract

Recent studies have shown that tumor cells acquire escape mechanisms to evade host immunity in the tumor microenvironment. Two key immune checkpoint pathways mediated by immunosuppressive co-signaling, the first via programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-1/PD-L1) and the second via CTLA-4 and B7 (CTLA-4/B7), have been previously described. Several clinical trials have revealed an outstanding anti-tumor efficacy of immune checkpoint inhibitors (anti-CTLA-4 antibody, anti-PD-1 antibody and/or anti-PD-L1 antibody) in patients with various types of solid malignancies, including non-small cell lung cancer, melanoma, renal cell cancer and ovarian cancer. In this review, we examine pre-clinical studies that described the local immune status and immune checkpoint signals in ovarian cancer, highlight recent clinical trials that evaluated immune checkpoint inhibitors against ovarian cancer and discuss the clinical issues regarding immune checkpoint inhibitors.

KEYWORDS:

CTLA-4; PD-1; PD-L1; biomarker; immunotherapy

PMID:
27055470
DOI:
10.1093/intimm/dxw020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center